SYLVIA AND CHARLES VIERTEL CHARITABLE FOUNDATION MARKS 30 YEARS MILESTONE IN FUNDING RESEARCH New Fellowships to researchers in cancer metastasis, epigenomics and AI in early disease diagnosis & management
With
Associate Professor Paul Ekert, Co-Chair,
Medical Advisory Board, Sylvia and Charles Viertel Charitable Foundation
SEGMENT
Filmed in Sydney, Melbourne & Adelaide | December 2025
One of Australia’s largest charitable foundations, the Sylvia and Charles Viertel Charitable Foundation, is celebrating three decades of transforming Australian healthcare – with more than $90 million invested in medical research and a legacy of breakthroughs that are saving lives. Viertel Fellowships support some of Australia’s best and brightest researchers and clinicians, with 70 Fellowships awarded to date.
In late October 2025, the Sylvia and Charles Viertel Charitable Foundation, in association with Bellberry, announced the recipients of the 2025 Viertel Senior Medical Research Fellowships. Three Australian mid-career researchers who are advancing solutions for major illnesses including cancer, cardiovascular disease, and neurodegenerative diseases. The 2025 Viertel Senior Medical Research Fellows, who will each receive $1.375 million over five years to support their work, are:
- Dr Joanna Achinger-Kawecka, SAiGENCI for her work in advancing cancer therapy utilising innovative 3D chromatin structure mapping technology.
- Dr Dustin Flanagan, Monash Biomedicine Discovery Institute, Monash University, for addressing the impact of direct cell damage on gastric cancer initiation and progression.
- Associate Professor Zongyuan Ge, Monash AIM for Health Lab, Monash University for developing a personalised healthcare model integrating diverse patient information collected over time via AI. He is the recipient of a Bellberry-Viertel Senior Medical Research Fellowship.
The Viertel Foundation over 30 years has had significant impact in medical research, including
- Awarding 70 fellowships since 1995, each currently providing $1.375 million over five years to support Australia’s top mid-career researchers.
- 162 Clinical Investigator Awards providing $90,000 over one year have been granted, supporting early-career clinicians and stimulating clinical research across Australia.
- Research infrastructure grants totalling $2.45 million have been awarded, recognising the importance of establishing and maintaining the facilities required for world-class research environments.
- The combined total value of the Clinical Investigator Awards, the Fellowships, and infrastructure grants – including the most recent awards has reached $90,001,250. This substantial investment underscores the Foundation’s enduring commitment to advancing medical research and improving health outcomes for Australians.
- Funding has enabled breakthroughs in cancer, infectious diseases, respiratory illnesses, dementia, stem cell research, and more – directly impacting millions of Australians each year.
Source: Adapted from Equity Trustees media release
Photo Credit: Charles Viertel Photo, Queensland Eye Institute
Photo Credit: AAHMS Gala Dinner, Canberra November 2025, Australian Academy of Health and Medical Sciences
-
Mission to raise awareness of sarcoma and need for clinical trial funding
Sarcoma, a rare and aggressive cancer, remains the deadliest cancer for children and young adults, accounting for nearly one third (30%) of cancer-related deaths among those aged 15–24 and one tenth (10%) of those aged 0–14. Further, still severely under-diagnosed, sarcoma only accounts for one sixth (15%) of all cancer diagnoses in the 15 – 24 age group, and less than a tenth (8%) among children under 10.
-
Implementing improvements in referral management and demand
Nalani Cox joined Gold Coast Health in 2019 as a Nurse Manager focused on improving referral management processes within the outpatient environment through the implementation of the Clinical Prioritisation Criteria. This work became a focus point for the organisation in 2020 when Nalani led an organisational wide change project introducing Smart Referrals, Refer Your Patient website and HealthPathways which has culminated in her position as the ADON of the Referral Strategy and Performance Department.
-
New option for management of high-risk soft tissue sarcoma of the limb
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
